Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 10 of 41
The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
NCT03270072
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
NCT03202940
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: a Cardiac MRI Study
NCT03238755
Evaluation of PET/MR in Patients Selected for Ablation Therapy
NCT03265431
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT03104439
Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy
NCT03459339
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
NCT02886065
Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease
NCT02909192
Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy
NCT02994693
Pembrolizumab In Central Nervous System Metastases
NCT02886585
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
NCT02826434
Circulating RNAs in Acute Congestive Heart Failure
NCT03345446
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT02718833
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
NCT02632344
A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
NCT02693990
Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study
NCT02632656
ASPirin Intervention for the REDuction of Colorectal Cancer Risk
NCT02394769
Effects of Weight Loss Surgery on Bone Health in Adolescents
NCT02557438
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
NCT02081326
Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis
NCT02412553
Surveillance and Image-Guided Biopsy of the Esophagus Using an OFDI Capsule
NCT02422433
Development of an Intervention to Enhance Cancer Pain Management
NCT03752268
Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS
NCT02087826
Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury
NCT01910818
Arthroscopic Labral Repair Versus Physical Therapy for Tears of the Acetabular Labrum
NCT03909178
Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus
NCT02202590
Bevacizumab/Doxorubicin/Radiation for Sarcoma
NCT01746238
High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull
NCT01346124
Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
NCT01617161
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01562405
Afatinib With CT and RT for EGFR-Mutant NSCLC
NCT01553942
Mechanism of Action of Transcranial Magnetic Stimulation
NCT04278521
Proton Radiation Therapy for Gliomas
NCT01358058
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
NCT01199978
Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors
NCT01049230
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
NCT01075672
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
NCT00977470
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
NCT01762046
Identifying Vulnerable Plaques in Blood Vessels of the Heart Using a New Imaging Technique
NCT00540761
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
NCT01115777
Genetic and Environmental Risk Factors Related to Esophageal Cancer
NCT01035398
Molecular Epidemiology of Acute Respiratory Distress Syndrome (ARDS)
NCT00006496
Mindfulness-based Neurofeedback to Reduce Negative Thinking in CHARMS Adolescents
NCT06901232
Intervention to Reduce Implicit Bias in Pharmacies
NCT06487351
A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerging Adults
NCT07214831
Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia Prevention
NCT07614893
A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior
NCT06686901
Metabolism Enhancement by Laser Therapy
NCT06899958
Feasibilty and Acceptability of Amani
NCT07648043
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.